Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atenativ for heparin-resistant adults undergoing cardiac surgery with cardiopulmonary bypass
ISRCTN55521313Phase 3Recruiting
- Sponsor
- Octapharma
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of antithrombin III concentrate in acquired antithrombin deficiency (AATD) and heparin resistance, sponsored by Octapharma. Primary endpoint: No additional antithrombin-containing therapy required through completion of cardiopulmonary bypass. Started Aug 2024; status: recruiting.
02
Drugs
antithrombin III concentrate
03
Conditions
acquired antithrombin deficiency (AATD)heparin resistance
Beyond the preview
Go deeper on ISRCTN55521313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN55521313.